BECTAS THERAPEUTICS, INC.

From the company

Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies for cancer, accompanied by biomarkers to identify patients who will most benefit from each therapeutic antibody. Its programs combine monoclonal antibodies targeting secondary immune checkpoints that regulate myeloid-dependent immune suppression with patient-selection biomarkers based on insights from human patients. The company was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT) to support pre